Bargahi N, Ghasemian A, Hoseinpoor R, Mahmoodi S
Department Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Arch Razi Inst. 2024 Dec 31;79(6):1155-1164. doi: 10.32592/ARI.2024.79.6.1155. eCollection 2024 Dec.
The rapid dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the 2019 coronavirus (COVID-19) pandemic on a global scale. An efficacious strategy to control the ongoing pandemic of the novel coronavirus disease (2019-nCoV) includes the rapid recognition of infected patients and the implementation of vaccination programs utilizing accurate and reliable methods. A variety of diagnostic techniques, including computed tomography (CT) scans, serological assays, and molecular methods, have been employed for the diagnosis of coronavirus disease 2019 (COVID-19). Furthermore, a variety of vaccines, antiviral drugs, and immunotherapies have been employed to combat the virus. This is of particular importance for patients diagnosed with SARS-CoV-2 infection who are at high risk of developing serious complications. The prognosis, diagnosis, vaccination, and treatment of COIVD-19 present a number of challenges, including variability in disease severity, the emergence of new variants, individual factors and immune responses, co-infections and complications, a lack of long-term data, psychological and social factors, the availability and accessibility of tests, the sensitivity and specificity of tests, variability in symptoms, mild or asymptomatic cases, a limited number of specific antiviral options, clinical heterogeneity, the lack of a universal treatment protocol, overburdened healthcare systems, the management of severe cases, long-term effects and post-COIVD-19 syndrome, vaccine hesitancy, global cooperation, and vaccine production capacity. This article presents an overview of the most recent advancements in the field of Coronavirus Disease 2019 (Covid-19), encompassing prognosis, diagnosis, vaccination, and therapy. It is of the utmost importance to consult reliable sources such as national health authorities and the World Health Organization (WHO) in order to obtain the latest information on the vaccination of individuals against the novel coronavirus, including details on eligibility, availability, and recommended protocols in any specific region. The range of available treatment options and strategies is subject to ongoing evolution. Healthcare professionals and researchers are assiduously striving to surmount the challenges inherent to therapy and to enhance the outcomes for those affected by SARS-CoV-2 infection. It is imperative that randomized clinical studies be conducted with the objective of identifying the most appropriate and proven treatment in order to reduce the prevalence of SARS-CoV-2 infection and to prevent the occurrence of future pandemics.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的迅速传播导致了全球范围内的2019冠状病毒病(COVID-19)大流行。控制新型冠状病毒病(2019-nCoV)当前大流行的有效策略包括快速识别感染患者以及采用准确可靠的方法实施疫苗接种计划。多种诊断技术,包括计算机断层扫描(CT)、血清学检测和分子方法,已被用于诊断2019冠状病毒病(COVID-19)。此外,多种疫苗、抗病毒药物和免疫疗法已被用于对抗该病毒。这对于被诊断为SARS-CoV-2感染且有发生严重并发症高风险的患者尤为重要。COVID-19的预后、诊断、疫苗接种和治疗存在诸多挑战,包括疾病严重程度的差异、新变种的出现、个体因素和免疫反应、合并感染和并发症、缺乏长期数据、心理和社会因素、检测的可获得性和可及性、检测的敏感性和特异性、症状的变异性、轻症或无症状病例、特定抗病毒选择有限、临床异质性、缺乏通用治疗方案、医疗系统负担过重、重症病例的管理、长期影响和COVID-19后综合征、疫苗犹豫、全球合作以及疫苗生产能力。本文概述了2019冠状病毒病(Covid-19)领域的最新进展,包括预后、诊断、疫苗接种和治疗。为了获取关于个人接种新型冠状病毒疫苗的最新信息,包括任何特定地区的资格、可获得性和推荐方案等详细信息,咨询国家卫生当局和世界卫生组织(WHO)等可靠来源至关重要。可用治疗选择和策略的范围在不断演变。医疗专业人员和研究人员正在不懈努力克服治疗中固有的挑战,并改善受SARS-CoV-2感染患者的治疗结果。必须开展随机临床研究,以确定最合适且经过验证的治疗方法,从而降低SARS-CoV-2感染的流行率并预防未来大流行的发生。